Evidence map›Paper›PMID 30640956›Full record

ArticlePLoS pathogens2019

Antagonistic paralogs control a switch between growth and pathogen resistance in C. elegans.

Kirthi C Reddy, Tal Dror, Ryan S Underwood, Guled A Osman, Corrina R Elder, Christopher A Desjardins, Christina A Cuomo, Michalis Barkoulas, Emily R Troemel

Abstract read
In one paragraph

Article in PLoS pathogens, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Novel infection byInfection and immunity · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. ThebioRxiv : the preprint server for biology · 2025
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kirthi C ReddyDivision of Biological Sciences, University of California, San Diego, La Jolla, CA United States of America.
Tal DrorDivision of Biological Sciences, University of California, San Diego, La Jolla, CA United States of America.ORCID 0000-0002-6454-6403
Ryan S UnderwoodDivision of Biological Sciences, University of California, San Diego, La Jolla, CA United States of America.
Guled A OsmanDepartment of Life Sciences, Imperial College, London, United Kingdom.
Corrina R ElderDivision of Biological Sciences, University of California, San Diego, La Jolla, CA United States of America.ORCID 0000-0003-3150-241X
Christopher A DesjardinsInfectious Disease and Microbiome Program, Broad Institute, Cambridge MA United States of America.ORCID 0000-0002-3160-4734
Christina A CuomoInfectious Disease and Microbiome Program, Broad Institute, Cambridge MA United States of America.ORCID 0000-0002-5778-960X
Michalis BarkoulasDepartment of Life Sciences, Imperial College, London, United Kingdom.
Emily R TroemelDivision of Biological Sciences, University of California, San Diego, La Jolla, CA United States of America.ORCID 0000-0003-2422-0473

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
Viral Genomics: evolution, spread, and host interactionsU19AI110818 · NIAID · BROAD INSTITUTE, INC. · PI SABETI, PARDIS CHRISTINE · 2014 to 2024
$66.5M
The Intracellular Pathogen Response Triggers Defense Against Co-evolved PathogensR01GM114139 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Emily R Troemel · 2015 to 2026
$3.1M
Probing organismal proteostasis through the response to intracellular infectionR01AG052622 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Emily R Troemel · 2017 to 2026
$2.7M
Probing organismal proteostasis through the response to intracellular infectionR56AG052622 · NIA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TROEMEL, EMILY R · 2016 to 2016
$388k
NIAID NIH HHS P30 AI036214NIAID NIH HHS U19 AI110818NIA NIH HHS R01 AG052622NIA NIH HHS R56 AG052622NIGMS NIH HHS R01 GM114139
6 · The paper itself

Abstract

Immune genes are under intense, pathogen-induced pressure, which causes these genes to diversify over evolutionary time and become species-specific. Through a forward genetic screen we recently described a C. elegans-specific gene called pals-22 to be a repressor of "Intracellular Pathogen Response" or IPR genes. Here we describe pals-25, which, like pals-22, is a species-specific gene of unknown biochemical function. We identified pals-25 in a screen for suppression of pals-22 mutant phenotypes and found that mutations in pals-25 suppress all known phenotypes caused by mutations in pals-22. These phenotypes include increased IPR gene expression, thermotolerance, and immunity against natural pathogens, including Nematocida parisii microsporidia and the Orsay virus. Mutations in pals-25 also reverse the reduced lifespan and slowed growth of pals-22 mutants. Transcriptome analysis indicates that pals-22 and pals-25 control expression of genes induced not only by natural pathogens of the intestine, but also by natural pathogens of the epidermis. Indeed, in an independent forward genetic screen we identified pals-22 as a repressor and pals-25 as an activator of epidermal defense gene expression. In summary, the species-specific pals-22 and pals-25 genes act as a switch to regulate a program of gene expression, growth, and defense against diverse natural pathogens in C. elegans.

Indexed as

AnimalsBiological EvolutionCaenorhabditis elegansCaenorhabditis elegans ProteinsGene Expression ProfilingGenetic TestingHost-Pathogen InteractionsCaenorhabditis elegans Proteins

Identifiers

PMID30640956
PMCPMC6347328

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.